Pruritus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Pruritus, or itching, is a prevalent complaint that dermatologists and primary care physicians frequently encounter. It is one of the most common dermatological issues, and although generally considered harmless, it can negatively impact a patient's well-being and become debilitating when severe. The dermatologic causes of pruritus include conditions such as xerosis (dry skin), atopic dermatitis, scabies, dermatitis herpetiformis, lichen simplex chronicus, psoriasis, lichen planus, contact dermatitis, fungal infections, insect bites, pediculosis (lice infestation), urticaria (hives), sunburn, polymorphous light eruption, pityriasis rosea, as well as triggers like electrostatic charges from nylon and wool friction, plaster of Paris casts, fiberglass, and other irritants. The itch can be classified into four categories: cutaneous itch, neuropathic itch, neurogenic itch, and psychogenic itch. Cutaneous itch, also known as pruritoceptive itch, is caused by skin inflammation. Neuropathic itch occurs due to damage to the nervous system along the afferent nerve pathway and is often observed in conditions like herpetic neuralgia, multiple sclerosis, and brain tumors. Neurogenic itch originates centrally without evidence of neuronal pathology, commonly seen in cholestasis. Lastly, psychogenic itch is associated with delusional states, such as parasitophobia. Histamine is the most prominent substance involved in mediating itch. It is stored in mast cells and keratinocytes. Antihistamines can help treat urticaria and other allergic causes of pruritus. However, apart from providing sedation to aid sleep, antihistamines do not consistently alleviate itch from all causes.
- In the United States alone, pruritus is a prevalent symptom leading to over 7 million ambulatory visits yearly.
Thelansis’s “Pruritus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pruritus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Pruritus across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pruritus Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment